The Technical Analyst
Select Language :
Ovid Therapeutics Inc [OVID]

Exchange: Nasdaq Global Select Sector: Healthcare Industry: Biotechnology

Ovid Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Ovid Therapeutics Inc is listed at the NASDAQ Exchange

0.00% $2.20

Last updated: 8 aug 2022 - 0:07

TimeZone: America/New_York


FUNDAMENTALS
MarketCap: 154.92 mill
EPS: -0.946
P/E: 0.000
Earnings Date: Aug 15, 2022
SharesOutstanding: 70.42 mill
Avg Daily Volume: 0.182 mill
RATING 2022-08-05
B+
Buy
RATINGDETAILS
Rating CashFlow: Strong Buy
Return On Equity: Neutral
Return On Asset: Neutral
DE: Neutral
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
4/201/212/213/214/211/22
Revenuen/an/a
Gr.Profitn/an/an/an/a
Ebit
Asset
Debtn/an/an/an/an/an/a
DISCOUNTED CASH FLOW VALUE
$5.41
(146.04%) $3.21
Date: 2022-08-08
Expected Trading Range (DAY)

$ 2.10 - 2.30

( +/- 4.64%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2022-07-01 Takeda Pharmaceutical Co Ltd Buy 1 250 Series A Convertible Preferred Stock
2022-07-01 Takeda Pharmaceutical Co Ltd Buy 1 250 Series A Convertible Preferred Stock
2022-07-01 Takeda Pharmaceutical Co Ltd Buy 5 750 000 Common Stock
2022-07-01 Takeda Pharmaceutical Co Ltd Buy 1 250 Series A Convertible Preferred Stock
2022-04-08 Bernstein Karen Buy 69 424 Stock Option (right to buy)
INSIDER POWER
94.53
Last 100 transactions
Buy: 15 161 448 | Sell: 34 017

Forecast: 16:00 - $2.20

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $2.20
Forecast 2: 16:00 - $2.20
Forecast 3: 16:00 - $2.20
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $2.20 (0.00% )
Volume 0.0357 mill
Avg. Vol. 0.182 mill
% of Avg. Vol 19.58 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Ovid Therapeutics Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Ovid Therapeutics Inc

RSI

Intraday RSI14 chart for Ovid Therapeutics Inc
The Live Chart for Ovid Therapeutics Inc
Profile picture for
            Ovid Therapeutics Inc

OVID

Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 54 full-time employees. The firm is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.

Last 10 Buy Signals
Date Signal @
ZRXUSDAug 8 - 00:050.360
CVCUSDAug 8 - 00:050.163
GASUSDAug 8 - 00:042.98
PIVXUSDAug 8 - 00:030.172
XMRUSDAug 8 - 00:03164.40
BNTUSDAug 8 - 00:030.604
GNOUSDAug 8 - 00:03163.76
NEBLUSDAug 8 - 00:030.641
UBQUSDAug 8 - 00:030.0421
LTCUSDAug 8 - 00:0261.32

Stock Peers

Company Price Change
OVID2.200.00%
ASRT3.99-0.25%
CTXR1.000-0.99%
CUE3.040.00%
DNAY2.226.73%
DRIO6.295.36%
IKNA6.007.91%
IOBT4.124.83%
RCEL7.252.55%
RNLX2.636.91%
SPPI1.06013.28%

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.